BiotechTube

E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopenic, Idiopathic

Conditions

Purpura, Thrombocytopenic, Idiopathic, Acute Idiopathic Thrombocytopenic Purpura, Chronic Thrombocytopenia

Trial Timeline

Feb 1, 2011 → Jun 1, 2011

NCT ID
NCT01327872

About E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food

E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food is a phase 1 stage product being developed by Eisai for Purpura, Thrombocytopenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT01327872. Target conditions include Purpura, Thrombocytopenic, Idiopathic, Acute Idiopathic Thrombocytopenic Purpura, Chronic Thrombocytopenia.

What happened to similar drugs?

1 of 20 similar drugs in Purpura, Thrombocytopenic, Idiopathic were approved

Approved (1) Terminated (1) Active (18)
❌Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
🔄Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
🔄EltrombopagNovartisPhase 3
🔄eltrombopag + placeboNovartisPhase 3
🔄Eltrombopag + IVIG infusionNovartisPhase 3
🔄eltrombopag olamine (SB-497115-GR)NovartisPhase 3
🔄Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01327872Phase 1Completed

Competing Products

20 competing products in Purpura, Thrombocytopenic, Idiopathic

See all competitors
ProductCompanyStageHype Score
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oralEisaiPhase 1
29
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
40
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
MK-8723 + Matching PlaceboMerckPhase 1
29
EltrombopagNovartisPhase 2
35
eltrombopagNovartisPhase 2
35
EltrombopagNovartisPre-clinical
26
EltrombopagNovartisPhase 3
36
eltrombopag + placeboNovartisPhase 3
40
Eltrombopag + IVIG infusionNovartisPhase 3
40
eltrombopag olamine (SB-497115-GR)NovartisPhase 3
40
Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3
40